Trimetazidine Dihydrochloride is indicated in adults as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are not adequately controlled by or are intolerant to first-line antianginal therapies.

Trimetazidine Dihydrochloride is the first 3-keto acyl CoA thiolase (KAT) inhibitor, a metabolic anti-ischemic agent with proven benefits in coronary patients. It inhibits fatty acid metabolism by blocking the 3-keto acyl CoA thiolase enzyme and shifts energy production toward glucose oxidation. Since glucose oxidation is more efficient, it enhances energy production using the same amount of oxygen, thereby improving cardiac function. Additionally, aerobic glucose metabolism reduces lactic acid formation, helping to prevent angina symptoms.

The recommended dose of Trimetazidine is 35 mg twice daily or 20 mg three times daily, taken with meals. Treatment effectiveness should be evaluated after three months, and the drug should be discontinued if there is no clinical improvement.

No drug interactions have been reported to date. Specifically, no interactions have been observed with beta-blockers, calcium channel blockers, nitrates, heparin, lipid-lowering agents, or digitalis preparations.

TTrimetazidine is contraindicated in patients with known hypersensitivity to the active substance or any of its components. It is also contraindicated in patients with Parkinson’s disease, parkinsonian symptoms, tremors, restless legs syndrome, or severe renal impairment.

Trimetazidine is generally safe and well tolerated. Common adverse effects include dizziness, headache, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, rash, pruritus, urticaria, and asthenia.

There are no adequate data on the use of Trimetazidine in pregnant women. Animal studies do not show direct or indirect harmful effects on reproductive toxicity; however, as a precaution, its use during pregnancy is not recommended. It is not known whether Trimetazidine is excreted in human milk. Since a risk to newborns or infants cannot be excluded, Trimetazidine should not be used during breastfeeding.

Trimetazidine is not a curative treatment for angina attacks, nor an initial treatment for unstable angina pectoris. It is also not a treatment for myocardial infarction.

Other Anti-anginal & Anti-ischaemic drugs.

Keep in a dry place away from light and heat. Keep out of the reach of children.